Sitryx Therapeutics Ltd., of Oxford, U.K., is collaborating with CRO Sygnature Discovery Ltd., of Nottingham, U.K., to discover multiple therapeutics in the immuno-oncology and immuno-inflammation spaces. Terms of the deal weren't disclosed. (See BioWorld, Oct. 9, 2018.)